Combination treatment for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a new combination of two drugs for cervical cancer that has returned or spread and did not get better with platinum-based chemotherapy. It aims to see if the combination works better than the standard treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have cervical cancer (squamous cell, adenocarcinoma, or adenosquamous) that cannot be cured with surgery, radiation, or chemo-radiation.
- You have tried a platinum-based chemotherapy (like cisplatin or carboplatin) and it did not stop the cancer.
- You have at least one tumor that can be measured on a scan.
- You are willing to provide a fresh or stored tumor sample for testing.
- You are able to take pills by mouth and can look after yourself (ECOG performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining two immunotherapy drugs with chemotherapy and sometimes another drug called bevacizumab, followed by radiation and chemotherapy. It aims to see if this approach can better treat advanced cervical cancer.
This trial tests two drugs together for people with cervical cancer that has returned or spread. The goal is to see if the combination can shrink tumors or slow the disease better than current options.
This study tests a combination of two drugs—utidelone (a chemotherapy-like drug that targets cell division) and toripalimab (an immunotherapy that helps your immune system attack cancer). It is for people with advanced cervical cancer that has not gone away or has spread, and who have already tried standard chemotherapy. The goal is to see if this combination can help control the cancer.
This study tests a new drug combination for people with advanced cervical cancer that has spread or returned after platinum-based chemotherapy. The goal is to see if this treatment can shrink tumors or slow the disease.
This trial tests a combination of an experimental pill (WX390) and an immunotherapy drug (Toripalimab) for a specific type of cervical cancer that has an STK11 gene change. It aims to see if this combination can shrink tumors or slow the cancer.
This trial tests a combination of new immunotherapy drugs (LB1410 and maybe LB4330) with lenvatinib (a targeted therapy) in patients with advanced cervical cancer that came back or spread. The goal is to see if this combo shrinks tumors or slows the cancer better than standard options.
Hear when a new Cervical Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.